image.jpg

Answer in detail

Reading File

Finding Sources

Reading File

I now have enough material from the textbooks combined with my medical knowledge to give a thorough answer to all questions. Let me compile the full detailed response.

Complete Answers to Gynaecology & Obstetrics Exam Paper

SECTION B - LONG QUESTION

IV. Physiology of the Normal Menstrual Cycle - Hormonal Regulation and Changes in the Ovary and Endometrium

Overview

The normal menstrual cycle averages 28 days (range 21-35 days) and is divided into:

Ovarian cycle: Follicular phase + Ovulation + Luteal phase
Endometrial (uterine) cycle: Proliferative phase + Secretory phase + Menstruation

Hormonal Regulation: The Hypothalamic-Pituitary-Ovarian (HPO) Axis

The HPO axis is the master regulator of the menstrual cycle.

Hypothalamus:

Neurons in the arcuate nucleus and preoptic area synthesize Gonadotropin-Releasing Hormone (GnRH).
GnRH is released in pulsatile fashion - approximately once per hour - into the hypothalamo-pituitary portal system.
Pulsatile GnRH upregulates GnRH receptors on pituitary gonadotrophs and stimulates FSH and LH secretion.
Continuous (non-pulsatile) GnRH causes downregulation of receptors and suppresses gonadotropin release (basis for GnRH agonist therapy in endometriosis).

Anterior Pituitary:

Responds to GnRH pulses by releasing FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone) from gonadotrophs.

Ovary:

Produces estrogens, progestins, inhibin, and activin.
These exert feedback (both negative and positive) on the hypothalamus and pituitary.

The Ovarian Cycle

Phase 1 - Follicular Phase (Days 1-14):

FSH rises at the start of the cycle (due to low estrogen/progesterone from the previous luteal phase demise).
FSH stimulates a cohort of primordial follicles to grow. One becomes dominant (Graafian follicle).
Granulosa cells of the growing follicle produce estradiol (the dominant estrogen).
Estradiol initially exerts negative feedback on FSH - FSH levels fall, and only the dominant follicle (most FSH-sensitive) survives; the others undergo atresia.
As the dominant follicle matures, rising estradiol levels eventually switch to positive feedback on the pituitary (when estradiol is >200 pg/mL for >50 hours), triggering the LH surge.

Ovulation (Day 14):

The mid-cycle LH surge (and smaller FSH surge) triggers ovulation ~36 hours after the surge.
The dominant follicle ruptures and releases the oocyte.
LH also causes luteinization of granulosa cells.

Phase 2 - Luteal Phase (Days 15-28):

After ovulation, the ruptured follicle transforms into the corpus luteum (under LH influence).
The corpus luteum secretes large amounts of progesterone and some estradiol.
Progesterone and estradiol together exert negative feedback, suppressing FSH and LH.
If no pregnancy occurs, the corpus luteum involutes (lifespan ~14 days), progesterone and estrogen fall sharply.
Falling progesterone triggers menstruation and allows FSH to rise again, starting a new cycle.

Changes in the Endometrium

Phase	Days	Hormone	Endometrial Change
Menstruation	1-4	Falling E + P	Functional layer shed; vasoconstriction then bleeding
Proliferative	5-14	Rising Estrogen	Endometrial glands and stroma proliferate; glands straight/tubular; thickness increases 2-10 mm
Secretory	15-28	Progesterone dominant	Glands become tortuous and secretory ("saw-tooth"); glycogen accumulates; stroma becomes edematous; ideal for implantation

Menstruation occurs when progesterone falls: constriction of spiral arteries causes necrosis and sloughing of the functional layer. The basal layer remains intact and regenerates.

Common Menstrual Disorders (Enumerate)

Dysmenorrhea - painful menstruation (primary or secondary)
Menorrhagia - heavy menstrual bleeding (>80 mL per cycle)
Oligomenorrhea - infrequent cycles (>35 days apart)
Polymenorrhea - frequent cycles (<21 days apart)
Amenorrhea - absence of menstruation (primary or secondary)
Metrorrhagia - irregular intermenstrual bleeding
Premenstrual syndrome (PMS) / PMDD
Hypomenorrhea - scanty menstruation

SECTION B - SHORT QUESTIONS (4×5=20)

V.1 - Inverted Pyramid of Antenatal Care

The Inverted Pyramid of Antenatal Care is a model that rationalizes the number of antenatal visits based on risk assessment, so that effort is concentrated where it is most needed - in contrast to the traditional pyramid where visits decrease over time.

Concept:

Traditionally, most visits were clustered in early pregnancy, fewer later. The inverted pyramid reverses this - more intensive surveillance in the third trimester when complications peak.
WHO's focused antenatal care model (now updated to 8+ contacts) recommends:
- Visit 1: Before 12 weeks - confirmation, dating, booking investigations
- Visit 2: 20 weeks - anomaly scan, anaemia assessment
- Visit 3: 28 weeks - glucose challenge test, repeat blood tests
- Visit 4: 32 weeks
- Visit 5: 36 weeks - presentation, final preparations
- Visit 6: 38 weeks, Visit 7: 40 weeks, Visit 8: 41 weeks

Components of the "Pyramid" Model (4 focuses):

Early registration and risk stratification
Health promotion and education (nutrition, iron/folic acid, immunization, birth preparedness)
Detection and management of complications (pre-eclampsia, anaemia, gestational diabetes, malpresentation)
Birth preparedness and complication readiness (where to deliver, emergency contacts, blood donor identification)

V.2 - Precocious Puberty

Definition: Development of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys.

Classification:

Type	Description
GnRH-dependent (central / true)	Premature activation of the HPO axis; LH/FSH-dependent
GnRH-independent (peripheral / pseudo)	Autonomous sex steroid production; HPO axis NOT activated

Causes - Girls:

Central (most common in girls - idiopathic ~80%): CNS tumors (hypothalamic hamartoma), CNS irradiation, hydrocephalus, neurofibromatosis
Peripheral: Ovarian cysts/tumors, adrenal tumors, McCune-Albright syndrome, exogenous estrogens

Causes - Boys:

Central: CNS lesions (hypothalamic hamartoma is most common)
Peripheral: CAH (congenital adrenal hyperplasia), Leydig cell tumors, hCG-secreting tumors

Clinical Features:

Breast development (thelarche), pubic/axillary hair (adrenarche), menstruation (menarche)
Advanced bone age leading to early epiphyseal fusion and short final adult height
Behavioral and psychosocial issues

Investigations:

Bone age (X-ray of wrist)
LH, FSH, estradiol/testosterone
GnRH stimulation test (LH rise >5 IU/L = central)
Pelvic/abdominal ultrasound
Brain MRI (to rule out CNS lesion)

Management:

Central: GnRH agonist (leuprolide depot) - monthly injections suppress HPO axis
Peripheral: Treat underlying cause (tumor excision, aromatase inhibitors, medroxyprogesterone)

V.3 - Syndromic Management of STI

Syndromic Management is the WHO-recommended approach for managing sexually transmitted infections (STIs) in resource-limited settings. It treats a patient based on the clinical syndrome (presenting complaint) rather than waiting for laboratory confirmation of a specific pathogen.

Principle: A treatment protocol is designed to cover the most common organisms causing that particular syndrome.

Common Syndromes and Treatment:

Syndrome	Likely Organisms	Treatment
Urethral Discharge (Male)	N. gonorrhoeae + C. trachomatis	Ceftriaxone 250 mg IM STAT + Doxycycline 100 mg BD × 7 days
Vaginal Discharge	Trichomonas, BV, Candida	Metronidazole 400 mg BD × 7 days ± Fluconazole for candida
Genital Ulcer Disease	Herpes, Syphilis, Chancroid, LGV, Donovanosis	Benzathine penicillin 2.4 MU IM + Acyclovir 400 mg TDS × 7 days + Erythromycin 500 mg QID × 7 days
Lower Abdominal Pain (PID)	N. gonorrhoeae, C. trachomatis, anaerobes	Ceftriaxone + Doxycycline + Metronidazole
Inguinal Bubo	LGV, Chancroid	Doxycycline 100 mg BD × 21 days
Neonatal Conjunctivitis	N. gonorrhoeae, C. trachomatis	Ceftriaxone IM + Tetracycline eye ointment

Advantages:

Immediate treatment at first visit - reduces loss to follow-up
No laboratory needed
Cost-effective
Reduces transmission

Disadvantage: Overtreatment possible; some etiologies missed (e.g., HSV not covered by standard urethral discharge protocol).

V.4 - MTP Act (Medical Termination of Pregnancy Act)

India's MTP Act 1971 (amended in 2021) governs the legal framework for termination of pregnancy.

Grounds for Termination (Section 3):

Ground	Description
Contraceptive failure	In any woman or her partner (amended 2021 to include all women, not just married)
Risk to life/physical health	Continuation endangers the woman's life
Risk to mental health	Pregnancy causes grave injury to mental health
Rape/incest	Anguish of rape constitutes mental health ground
Fetal abnormalities	Substantial risk of serious handicap in the child

Gestational Limits (Post-2021 Amendment):

Weeks	Requirement
Up to 20 weeks	Opinion of 1 registered medical practitioner (RMP)
20-24 weeks	Opinion of 2 RMPs; only for specified categories (survivors of rape, minors, differently-abled women, multi-fetal pregnancy, etc.)
Beyond 24 weeks	Only for fetal abnormalities; requires approval of State-level Medical Board

Place of Termination:

Government hospital, or
Place approved by CMO/District Level Committee

Key Provisions:

Confidentiality is mandatory - identity of the woman shall not be revealed (punishable with up to 1 year imprisonment for breach)
The woman's consent is required; for minors/mentally ill - guardian's consent
Husband's consent is NOT required
Registered Medical Practitioner (RMP) must have training in termination of pregnancy

SECTION B - SECTION VI: BRIEFLY EXPLAIN (5×2=10)

VI.1 - Maternal Mortality Ratio (MMR): Definition and Calculation

Definition (WHO): "The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of pregnancy, from any cause related to or aggravated by the pregnancy or its management, but not from unintentional or incidental causes."

Formula:

MMR = (Number of maternal deaths / Number of live births) × 100,000

Expressed per 100,000 live births
The denominator is live births (not all pregnancies), as this is the most readily available data

Types of Maternal Deaths:

Direct Obstetric Deaths - from obstetric complications (hemorrhage, eclampsia, sepsis, obstructed labor, unsafe abortion, complications of anesthesia)
Indirect Obstetric Deaths - from pre-existing disease aggravated by pregnancy (cardiac disease, anemia, malaria, HIV)
Late Maternal Deaths - from direct/indirect causes, 42 days to 1 year after delivery

India's MMR: Approximately 97/100,000 live births (SRS 2018-20), down from 254 in 2004-06.

Global target (SDG 3.1): Reduce MMR to <70/100,000 live births by 2030.

VI.2 - Vaccines Recommended During Pregnancy

Vaccine	Dose/Schedule	Purpose
Tetanus Toxoid (TT) / Td / Tdap	TT1 - as early as possible in pregnancy; TT2 - 4 weeks after TT1; Booster if within 3 years. Tdap preferred in third trimester (27-36 wks)	Maternal and neonatal tetanus prevention
Influenza (Inactivated)	Single dose, any trimester	Prevents influenza and complications; also protects newborn via maternal antibodies
COVID-19	As per national schedule	Reduces severity of infection
Hepatitis B	If unimmunized and at risk	Prevents HBV transmission to neonate

Vaccines CONTRAINDICATED in pregnancy:

Live vaccines: MMR, Varicella, BCG, Yellow Fever (unless high risk)

VI.3 - Indications for Blood Transfusion in Obstetrics

Any Four:

Antepartum Hemorrhage (APH) - Placenta previa or placental abruption with significant blood loss (Hb <8 g/dL or hemodynamic instability)
Postpartum Hemorrhage (PPH) - >500 mL loss after vaginal delivery or >1000 mL after cesarean; transfuse if Hb falls <7-8 g/dL with symptoms
Severe Anemia in Pregnancy - Hb <7 g/dL near term (especially if symptomatic or delivery imminent) - packed red cells preferred
Ectopic Pregnancy with Hemoperitoneum - Ruptured ectopic with hypovolemic shock
Disseminated Intravascular Coagulation (DIC) - In association with abruption, amniotic fluid embolism, sepsis - FFP, platelets, cryoprecipitate also needed
Surgical hemorrhage during cesarean section or hysterectomy

Principles of obstetric transfusion:

Use typed and cross-matched blood whenever possible
In emergencies: O-negative uncross-matched blood may be used
Target Hb: ≥8 g/dL (symptomatic) or ≥10 g/dL (near term/perioperative)

VI.4 - Preconceptional Counselling: Components

Definition: Advice and interventions given to women/couples planning a pregnancy to optimize health outcomes for mother and baby.

Any Four Components:

Medical History Review
- Identify chronic diseases (diabetes, hypertension, epilepsy, thyroid disorders, SLE)
- Review and adjust medications (e.g., switch teratogenic drugs - switch ACE inhibitors, warfarin, valproate to safer alternatives)
- Screen for genetic disorders and family history
Nutritional Optimization
- Start Folic acid 400 mcg/day at least 1 month before conception (reduces neural tube defects by 70%)
- High-risk women (previous NTD baby, on antiepileptics): 5 mg/day folic acid
- Assess BMI; optimize weight (obesity increases risk of GDM, pre-eclampsia, NTD)
- Iron, iodine supplementation if deficient
Immunization Update
- Rubella immunity (MMR if non-immune - wait 1 month before conception)
- Varicella, Hepatitis B vaccination if non-immune
- Influenza, COVID-19
Lifestyle Modification
- Stop smoking (increases miscarriage, IUGR, preterm birth, SIDS)
- Avoid alcohol (fetal alcohol spectrum disorder)
- Avoid recreational drugs
- Avoid teratogenic occupational exposures
Genetic Counselling (if applicable)
- Previous child with chromosomal anomaly/congenital defect
- Advanced maternal age (>35 years)
- Consanguineous marriage
- Carrier status for autosomal recessive disorders (thalassemia, sickle cell)
Infection Screening
- Screen and treat STIs, UTIs, bacterial vaginosis
- TORCH screening (Toxoplasma, Rubella, CMV, Herpes)
- HIV testing and counselling

VI.5 - Tests Used for Assessment of Fetal Well-being

Test	Details
1. Fetal Movement Count (Kick Count)	Maternal monitoring; Cardiff "count to 10" method - 10 movements in 12 hours is reassuring; simple, non-invasive, daily monitoring
2. Non-Stress Test (NST)	Cardiotocography (CTG) monitoring fetal heart rate without stress; Reactive NST (≥2 accelerations of ≥15 bpm for ≥15 sec in 20 min) = reassuring; most widely used test
3. Contraction Stress Test (CST) / Oxytocin Challenge Test (OCT)	FHR response to uterine contractions induced by oxytocin; Negative CST (no late decelerations) = reassuring; Positive CST = uteroplacental insufficiency
4. Biophysical Profile (BPP)	Ultrasound assessment of 5 parameters (each scored 0 or 2): Fetal breathing movements, Gross body movements, Fetal tone, Amniotic fluid volume (AFI) + NST; Score 8-10 = normal, ≤4 = deliver
5. Modified BPP	NST + Amniotic Fluid Index (AFI) only; widely used for surveillance
6. Doppler Velocimetry	Umbilical artery, middle cerebral artery (MCA), ductus venosus Doppler; absent/reversed end-diastolic flow in umbilical artery = severe placental insufficiency; MCA pulsatility index reflects fetal redistribution ("brain-sparing")
7. Amniotic Fluid Assessment (AFI)	AFI <5 cm = oligohydramnios (IUGR, post-dates, fetal anomalies); AFI >24 cm = polyhydramnios

This covers all questions in the exam paper:

Section B Long Question (IV): Full menstrual cycle physiology with hormonal regulation, ovarian changes, endometrial changes, and menstrual disorders
Section V Short Questions (1-4): Inverted pyramid of ANC, precocious puberty, syndromic STI management, MTP Act
Section VI Brief Answers (1-5): MMR definition and calculation, vaccines in pregnancy, blood transfusion indications, preconceptional counselling components, fetal well-being tests

This is a shared conversation. Sign in to Orris to start your own chat.